RTO Stock Recent News

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or the "Company") (NYSE:RTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.

NEW YORK CITY, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE:RTO). Investors who purchased Rentokil securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RTO.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rentokil Initial plc (“Rentokil” or “the Company”) (NYSE: RTO). Investors who purchased Rentokil securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RTO .

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or the "Company") (NYSE:RTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.

NEW YORK CITY, NY / ACCESSWIRE / September 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE:RTO). Investors who purchased Rentokil securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RTO.

NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.